It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Undifferentiated pleomorphic sarcoma (UPS) is the largest subgroup of soft tissue sarcomas. This study determined the value of perfusion-weighted imaging with dynamic-contrast-enhancement (PWI/DCE) morphologic, qualitative, and semiquantitative features for predicting UPS pathology-assessed treatment effect (PATE). This retrospective study included 33 surgically excised extremity UPS patients with pre-surgical MRI. Volumetric tumor segmentation from PWI/DCE was obtained at Baseline (BL), Post-Chemotherapy (PC), and Post-Radiation Therapy (PRT). The surgical specimens’ PATE separated cases into Responders (R) (≥ 90%, 16 patients), Partial-Responders (PR) (89 − 31%, 10 patients), and Non-Responders (NR) (≤ 30%, seven patients). Seven semiquantitative kinetic parameters and maps were extracted from time-intensity curves (TICs), and 107 radiomic features were derived. Statistical analyses compared R vs. PR/NR. At PRT, 79% of R displayed a “Capsular” morphology (P = 1.49 × 10-7), and 100% demonstrated a TIC-type II (P = 8.32 × 10-7). 80% of PR showed “Unipolar” morphology (P = 1.03 × 10-5), and 60% expressed a TIC-type V (P = 0.06). Semiquantitative wash-in rate (WiR) was able to separate R vs. PR/NR (P = 0.0078). The WiR radiomics displayed significant differences in the first_order_10 percentile (P = 0.0178) comparing R vs. PR/NR at PRT. The PWI/DCE TIC-type II curve, low WiR, and “Capsular” enhancement represent PRT patterns typically observed in successfully treated UPS and demonstrate potential for UPS treatment response assessment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The University of Texas, MD Anderson Cancer Center, Department of Musculoskeletal Imaging, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
2 The University of Texas, MD Anderson Cancer Center, Department of Surgical Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
3 The University of Texas, MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
4 The University of Texas, MD Anderson Cancer Center, Department of Imaging Physics, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
5 The University of Texas, MD Anderson Cancer Center, Department of Anatomical Pathology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
6 The University of Texas, MD Anderson Cancer Center, Department of Radiation Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)